Lynoo Pharmaceutical Packaging puts glass substrates first in Hong Kong listing plan
Jinan-based borosilicate glass maker Lynoo Pharmaceutical Packaging names industrialisation of glass substrates for semiconductor packaging, including a 4.8 million-piece-a-year line at its Jinan plant, as the main use of proceeds from the Hong Kong listing it applied for on 28 September 2026. Upgrades to its pharmaceutical glass business come second, and no fundraising target has been disclosed. Pharmaceutical glass revenue fell to USD 54m (CNY 357m) in 2025 from USD 70m (CNY 467m) in 2024.
Why this mattersA borosilicate pharmaceutical glass supplier is steering new capital to semiconductor substrates as its drug packaging revenue shrinks under Chinese healthcare cost controls and volume-based procurement.
- Lynoo Pharmaceutical Packaging filed its Hong Kong listing application on 28 September 2026
- Planned glass substrate line at the Jinan plant has 4.8 million pieces a year of capacity, covering melting, forming, cutting, grinding and polishing
- A single large production furnace is estimated to cost USD 120m-150m (CNY 800m-1,000m)
- Pharmaceutical glass packaging revenue fell to USD 54m (CNY 357m) in 2025, 36.3% of total revenue, from USD 70m (CNY 467m) in 2024
- Household heat-resistant glass revenue rose to USD 91m (CNY 609m) in 2025, 62.1% of total revenue
- The company renamed itself from Linuo Special Glass to Lynoo Pharmaceutical Packaging in November 2024